4.6 Article

Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis

Journal

BRITISH JOURNAL OF HAEMATOLOGY
Volume 192, Issue 3, Pages 560-567

Publisher

WILEY
DOI: 10.1111/bjh.17281

Keywords

NLPHL; relapsed; refractory; salvage therapy; survival

Categories

Funding

  1. NIH Clinical Center [CA016672] Funding Source: Medline
  2. Lymphoma Research Foundation Funding Source: Medline

Ask authors/readers for more resources

NLPHL patients with relapsed or progressive disease after initial treatment showed a median progression-free survival of four years after front-line treatment, with chemotherapy, biological therapy, stem cell transplant, and radiation therapy being common second-line treatments. Despite the good five-year progression-free survival rate of 68% after second-line therapy, the overall survival remained excellent at 94%. Further studies are needed to understand the biology of NLPHL and guide therapy de-escalation.
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare entity, with limited data on the outcome in the relapsed/refractory setting. We evaluated the outcome of all patients diagnosed between 04/1979 and 01/2019 with relapsed or progressive NLPHL after initial active therapy at two institutions, refractory disease being defined as lack of response to treatment and/or relapse within three months of treatment. NLPHL patients with histological evidence of transformation at time of first relapse or progression were excluded. In total, 69 patients with recurrent NLPHL were included in the study. After a median follow-up after initial diagnosis of 14 years (range, 0 center dot 5-46 years), median progression-free survival after front-line treatment (PFS-1) was four years. Second-line therapy included chemotherapy in 28 (41%) patients, biological therapy (rituximab, lenalidomide or brentuximab vedotin) in 14 (20%), high-dose chemotherapy followed by autologous stem cell transplant in 14 (20%) and radiation therapy (RT) alone in 10 (15%). The five-year PFS after second-line therapy (PFS-2) was 68% [95% confidence interval (CI), 54-79%] but the five-year overall survival (OS) after second-line therapy (OS-2) remained excellent, at 94% (95% CI, 85-99%). Due to excellent outcome in case of recurrence, studies aimed at characterizing its biology to guide therapy de-escalation are needed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available